How do I hire a fractional VP of Sales for a healthtech company in 2027?

The job a fractional sales leader is actually hired to do

Founders often reach for a fractional VP of Sales because payroll math looks scary, but cost is the second reason at best. The first reason is that healthtech revenue has a shape most founders have never operated. You are selling into a buying committee that spans clinical, financial, legal, IT, and sometimes compliance — and each of those seats can stall a deal indefinitely without ever formally saying no. A founder-led motion can carry a company to a handful of design partners on relationships and product credibility. It usually cannot carry a company to a repeatable process, because the founder is the process.

The fractional VP is hired to convert that founder-shaped motion into a system somebody else can run. That means a small number of concrete artifacts, not vibes. A qualification framework that reflects real healthcare buying: who signs, who blocks, who the clinical champion is, and what the budget cycle looks like. A stage definition set where every stage has an exit criterion tied to buyer behavior rather than seller optimism — "security review scheduled" is a stage gate, "they seemed excited" is not. A forecast that survives contact with a board meeting. And a discovery script that gets to the operational pain fast, because healthcare buyers have limited patience for vendors who need three calls to understand how a clinic actually schedules patients.

There's a second job, less discussed and often more valuable: telling you the truth about your stage. A good fractional leader will sometimes conclude that you do not have a sales problem — you have a product-market fit problem, a pricing problem, or an implementation-capacity problem masquerading as a pipeline problem. In healthtech this is common. Deals stall because your implementation team can only onboard two health systems a quarter, or because your product requires an EHR integration you cannot deliver on the timeline the buyer expects. Hiring a sales leader to fix that is like hiring a driver for a car with no engine. The fractional format is actually the right way to discover this, because six months of a retainer is a survivable diagnostic cost, while a full-time VP hire with equity and a severance conversation is not.

The third job is hiring and coaching. Most fractional engagements include building the first real sales team — writing the scorecard, interviewing candidates, structuring comp, and ramping the first one or two account executives. A fractional leader who has hired healthcare AEs before knows the profile is unusual: you need someone patient enough for an 11-month cycle, credible enough to talk to a CMIO without embarrassing themselves, and disciplined enough to work a multi-threaded deal across a year. That person is not the same profile as a high-velocity SMB SaaS closer, and hiring the wrong one costs you a full sales cycle to discover.

Where the role sits in the RevOps stack and who it touches

A fractional VP of Sales does not operate in isolation. In practice the role sits at the junction of four functions — marketing, sales operations, customer success, and finance — and the quality of the engagement depends heavily on whether those adjacent functions exist yet. If you have no marketing engine and no RevOps person, your fractional VP will spend the first month doing data cleanup and lifecycle-stage definition instead of selling, and you should price that expectation into the scope up front.

The most common structural mistake is hiring a fractional VP of Sales when the actual gap is systems. If your CRM has three duplicate records per account, no consistent close-date discipline, and opportunity stages that nobody follows, a senior sales leader is an expensive person to spend six weeks in a data-hygiene project. In that case, sequence a fractional or contract RevOps resource first — or hire the sales leader with an explicit line item for a part-time ops contractor working under them. Many fractional leaders travel with a preferred ops person for exactly this reason, and the combined cost is frequently lower than a single full-time VP.

The customer success handoff matters more in healthtech than almost anywhere else, because your buyers evaluate you partly on implementation risk. A deal closed with an over-promised go-live date becomes a churn event and a bad reference in a market where reference calls between health systems are routine and brutally candid. A fractional VP who has lived through a bad healthcare implementation will build the handoff gate into the sales process — scoping call before contract, implementation lead present on the final call, written go-live assumptions in the order form.

Finance is the fourth touchpoint and the one founders forget. In healthtech, contract structure is a revenue variable: per-provider pricing versus per-member-per-month versus flat platform fee changes both your ACV and your forecastability. A fractional VP with healthcare depth will have opinions about which structures survive procurement and which get shredded. They should be working with whoever owns your model, not operating downstream of it.

Engagement models, pricing structure, and what actually varies

Fractional engagements cluster into a few recognizable shapes, and knowing which one you're buying prevents most disputes later.

The retained day-rate model is the most common. You buy a defined number of days per month — 10 to 15 is the typical band for a leader who is genuinely running the function rather than just advising — at a monthly retainer. Fewer than eight days a month generally cannot support hands-on deal work; it becomes advisory. More than fifteen and you are approaching a fractional leader's full capacity, at which point you should ask whether you're actually buying a full-time hire with worse terms.

The advisory model is materially cheaper and materially less useful for execution. Two to four days a month buys you strategy sessions, pipeline review, and hiring input, but the leader is not in your deals. This works if you already have a competent sales manager who needs a coach, and does not work if you need someone to build the function from nothing.

The interim model is the opposite end: near-full-time, usually 3 to 6 months, typically to bridge a departure or to run a specific motion like a first enterprise push. Interim engagements cost more per month than fractional ones and usually carry a defined end date rather than a rolling renewal.

Equity participation appears in most fractional arrangements at earlier stages, generally as a small option grant on standard vesting with a cliff — commonly cited ranges for fractional executive roles run well below the 1–3% typical of a full-time VP hire, and shrink as the company's stage advances. Some founders trade cash down for equity up when runway is tight; be careful here. A fractional leader who accepts a heavy equity discount may be optimizing for portfolio breadth over your outcomes, and you have less leverage to demand intensity from someone you're underpaying in cash.

The variables that actually move price, in rough order of impact: days per month, seniority and named-brand track record, whether the engagement includes closing deals directly or only building process, whether hiring is in scope, and geography — though remote work has compressed the geographic spread considerably. Healthcare domain depth carries a real premium because the pool is smaller. Someone who has personally closed multi-year health system contracts is scarcer than someone who has closed mid-market SaaS, and prices accordingly.

Budget for the things founders forget. Travel to conferences and to on-site buyer meetings — healthcare still closes in rooms more than most software categories, and HIMSS, ViVE, and HLTH are real pipeline events, not junkets. Tool licenses if your leader wants call recording or forecasting software. And a ramp allowance: a fractional VP's first month is largely diagnostic, so if you sign a 6-month deal you are really buying 5 months of execution.

Structure payment in a way that keeps both parties honest. A common approach is a flat monthly retainer with a modest variable component tied to specific milestones — playbook delivered, first two AEs hired and ramped, a defined number of qualified enterprise opportunities created. Pure commission-only fractional arrangements almost never work in healthtech, because the sales cycle is longer than the engagement. If the cycle is 9 to 14 months and the engagement is 6 months, a commission-only leader is being asked to work for free and will behave accordingly.

The healthtech-specific filter that separates real candidates from résumés

General sales leadership does not transfer cleanly into healthcare. The filter has three layers, and you should run all three.

Layer one: buyer literacy. Ask a candidate to walk you through the buying committee at a mid-sized hospital system for a product like yours. A real healthcare seller will name roles without prompting — CMIO, CNIO, CFO, VP of revenue cycle, IT security, supply chain or value-analysis committee, and the clinical department head who actually feels the pain. They will tell you which of those is the champion, which is the economic buyer, and which is the one who kills deals quietly. They will mention that many systems route new clinical software through a value analysis committee that meets monthly, and that missing one meeting costs you a month. If a candidate answers this question in generic enterprise-SaaS language — "we'd map the org and multi-thread" — they've read the theory but haven't lived it.

Layer two: compliance and procurement mechanics. Healthcare deals carry a paperwork layer that stalls sellers who've never seen it. A business associate agreement under HIPAA is standard for anyone touching protected health information, and negotiating one can take weeks. Security reviews are routine and often include questionnaires or a SOC 2 request. If your product makes clinical claims, regulatory posture — whether the software is a regulated medical device, whether it's been through FDA clearance — is a gating question buyers will ask early. If you sell into government payers or public health systems, expect procurement rules, RFPs, and formal bid processes that a commercial-only seller has never navigated. Ask candidates what stalled their last healthcare deal. The honest ones will name a security review or a legal redline, not "budget."

Layer three: proof of a built pipeline. "I've sold into healthcare" is not a credential. Ask for one deal in detail: how it sourced, who the champion was, how long it took, what nearly killed it, and what the final contract structure looked like. Then ask for a reference who can confirm it — ideally a founder or CRO who worked with them, not a peer. The specificity of the answer is the signal. Someone who genuinely ran a healthcare motion can talk for twenty minutes about a single deal without notes.

There's a subtlety worth flagging: healthtech is not one market. Selling a scheduling tool to independent clinics, selling analytics to a payer, selling a workflow product to a 900-bed academic medical center, and selling software to a pharma commercial team are four different sales jobs with different cycles, different committees, and different price points. A candidate with deep payer experience may be nearly useless on provider deals and vice versa. Match the sub-segment, not the industry label.

Finally, evaluate for the fractional format itself, which is a distinct skill. Fractional leaders serve multiple clients simultaneously. You want someone who is candid about their portfolio — how many clients, what their capacity ceiling is, and how they'll handle a conflict when two clients hit a crisis in the same week. Ask directly. Someone who bristles at the question is someone whose attention you will be competing for silently.

A decision framework for founders choosing between structures

The question is rarely "fractional or nothing." It's usually fractional versus a full-time VP versus a senior AE who can lead versus keeping the founder in the seat with a coach. Each has a stage where it's correct.

Keeping the founder selling is right longer than most founders want to hear. If you're pre-repeatability — under a handful of closed customers, still learning which ICP converts — nobody can build a playbook because there isn't one yet to document. The founder's job at that stage is to find the pattern. A fractional leader can help you run better discovery and instrument what you're learning, but hiring one to "own sales" before there's a pattern usually produces an expensive six months of process built on sand.

Fractional is right when you have signal but not system: a set of closed customers you can point to, a repeating ICP starting to emerge, and either a founder whose time is now the constraint or a first AE who needs management. It's also right when you genuinely cannot yet justify the full-time comp package and the equity dilution — and honestly, when you aren't sure whether the role you'd hire full-time is a VP of Sales or a CRO. Six months with a fractional leader answers that question with data instead of a guess.

Full-time becomes correct when the function needs daily presence: multiple reps, a real quota model, and a hiring plan that runs continuously. The tell is usually that your fractional leader starts saying they're the bottleneck — that decisions are waiting for their day on-site. A good fractional leader will tell you when they've outlived the arrangement, and will often help you hire their replacement. That's the mark of a good one.

Run this framework honestly and it will occasionally tell you not to hire anyone yet. That's a valid output. The most expensive outcome in early revenue leadership is hiring a senior person into a role that doesn't exist yet, then blaming them when the underlying problem — undifferentiated product, unclear ICP, delivery capacity — reasserts itself.

Structuring the engagement so it produces something durable

The difference between a fractional engagement that leaves an asset behind and one that leaves a hole is almost entirely in how the contract was written.

Define deliverables, not hours. "15 days a month" is an input; nobody can evaluate it. Write down what exists at the end that didn't exist at the start: a written playbook covering ICP, discovery, objection handling, and pricing guardrails; a configured CRM with stage definitions and exit criteria; a documented forecast process with a cadence somebody on your team runs; a hiring scorecard and however many hired-and-ramped reps you agreed on; and a target for qualified enterprise opportunities created. Attach rough timing to each. Month one is diagnosis and playbook drafting. Months two and three are implementation and hiring. Months four through six are execution and handoff.

Name the successor from day one. The single most useful clause in a fractional agreement is knowledge transfer: who on your permanent team is being trained to run this after the engagement ends. If the answer is "nobody," you are renting a function rather than building one, and you should either extend indefinitely or accept that you'll rebuild from zero when they leave. Founders who designate an internal counterpart — even a strong AE or an ops person — get dramatically more residual value.

Set a review cadence with teeth. Monthly written updates against the milestone list, and a formal go/no-go at month three. Both sides should have a 30-day out. This protects you from a bad fit and protects them from a company that pivots or runs out of runway, and its existence makes both parties more willing to be direct earlier.

Handle the trial thoughtfully. A short paid diagnostic — two weeks, scoped as an audit of your current motion with a written findings document — is a reasonable way to test fit before a six-month commitment, and serious operators are generally happy to do paid work. Unpaid "sample strategy decks" are a different thing: asking a senior operator to produce speculative work for free filters for the least busy candidates, which is not the filter you want.

Plan the exit before you need it. The taper is usually better than the cliff: as the engagement winds down, step from fifteen days to eight to four over the final two months while the internal owner takes over the pipeline review and the forecast call. Companies that do this retain the process. Companies that end abruptly watch the CRM discipline decay within a quarter.

One adjacent note worth making, because the pattern generalizes: everything above applies nearly unchanged to fractional CRO, fractional marketing leadership, and fractional RevOps engagements. The domain filter changes — you'd be probing for demand-gen or systems depth instead of healthcare buying committees — but the structure, the milestone discipline, the named successor, and the taper are the same. If the fractional model works for you once, it tends to become how you staff senior functions through the awkward middle stage generally, and healthtech companies with long cycles and thin early teams hit that awkward middle stage in more functions than most.

Related questions

How long should a fractional VP of Sales engagement run?

Three to six months minimum. Month one is diagnostic, so shorter deals buy almost no execution. Beyond nine to twelve months, ask whether the function now needs daily presence — that's usually the signal to convert to a full-time hire or taper to advisory.

Should a fractional VP of Sales carry a quota?

Rarely a full one. Healthtech cycles routinely exceed the engagement length, so quota-based comp punishes the leader for timing they don't control. Tie variable pay to leading indicators instead: qualified opportunities created, reps hired and ramped, playbook and forecast delivered.

What's the difference between a fractional VP of Sales and a fractional CRO?

A VP of Sales owns the selling motion — team, pipeline, deals. A CRO owns the whole revenue system, including marketing, customer success, and revenue operations. Earlier-stage companies usually need the narrower role; the CRO scope matters once multiple revenue functions must be coordinated.

Can a fractional leader hire our first sales reps?

Yes, and it's often the highest-value part of the engagement. They write the scorecard, screen, interview, and ramp. They typically won't handle HR administration, offer paperwork, or compliance — budget for a recruiter or handle that internally.

Does healthcare domain experience really matter, or can a strong generalist learn it?

It matters enough to be a hard filter. The buying committee, procurement mechanics, and compliance paperwork take a cycle or more to learn — and a cycle in healthtech can be a year. In a six-month engagement, you're paying for knowledge that already exists.

FAQ

How do I write the brief before I start looking?

One page. Current ARR and growth rate, how many customers you've closed and how each one sourced, your target buyer by sub-segment (independent clinics, health systems, payers, life sciences), typical cycle length and ACV, what your CRM currently looks like, what your team is today, and the three outcomes you want at month six. Candidates will self-select against this, and the specificity of their response is itself a signal.

What are the warning signs during the interview process?

Generic answers about healthcare buying. Inability to name a stalled deal and why it stalled. Reluctance to discuss how many other clients they serve. Pushing for equity-heavy comp before understanding your business. Promising a specific revenue number in month two — in a market with double-digit-month cycles, that promise is either uninformed or dishonest. And any candidate who won't give you a reference from a founder they worked for.

How do we handle it if the fractional VP and our founder disagree on strategy?

Build the disagreement mechanism into the cadence. Monthly written updates should include an explicit "where we disagree" line. Most fractional engagements fail quietly — the leader stops pushing because pushing costs them a client, and the founder gets an expensive yes-person. Ask for dissent directly and reward it when you get it, or you're paying senior rates for agreement.

Should the fractional VP have access to our board materials?

Generally yes for the revenue sections, and they should help build them. A leader who's presented healthcare revenue forecasts to investors before will save you from the classic error of forecasting a long-cycle pipeline like a short-cycle one. Keep them out of cap table and financing discussions unless there's a specific reason; that's outside the scope you're buying.

What happens to the pipeline when the engagement ends?

This is exactly why the named-successor clause matters. Open opportunities should be formally reassigned with written context — champion, blockers, next step, history — at least three weeks before the last day, and the successor should sit in on the calls during the taper. Pipeline that lives only in a departing leader's head is pipeline you will lose.

Is a fractional hire actually cheaper, or does it just look cheaper?

It's genuinely cheaper in total cost — no benefits, no payroll taxes, less equity, no severance risk — but the honest framing is that you're buying less coverage, not the same coverage discounted. Ten to fifteen days a month is ten to fifteen days. The value comes from the seniority-per-dollar and the optionality to stop, not from getting a full-time executive at a discount.

Sources

• Health Level Seven International — interoperability standards
• HHS.gov — HIPAA business associate guidance
• U.S. FDA — Digital Health Center of Excellence
• HealthIT.gov — ONC health IT certification program
• CMS.gov — value-based programs
• HIMSS — health information and technology society
• Harvard Business Review — sales topic archive
• First Round Review — startup operating advice
• SaaStr — SaaS sales and leadership content
• Pavilion — community for revenue leaders

Related on PULSE

• How to structure a fractional CRO engagement at seed stage
• Building a sales playbook when the founder is still the best closer
• What a healthtech buying committee actually looks like
• When to hire your first AE versus your first sales leader
• Forecasting long-cycle enterprise pipeline without lying to your board
• RevOps foundations: CRM stage definitions that survive a board meeting